Ocrelizumab Demonstrates Superior Control of Multiple Sclerosis Relapses in Multi-Registry Study
A large multi-registry study shows that ocrelizumab provides better control of MS relapses compared to other high-efficacy therapies, highlighting its potential for managing disease activity in multiple sclerosis.
A comprehensive study presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) reveals that ocrelizumab, a monoclonal antibody targeting CD20+ B cells, offers more effective relapse control in multiple sclerosis (MS) compared to other high-efficacy therapies like fingolimod, natalizumab, and alemtuzumab.
This research utilized real-world data from three large MS registries: MSBase, OFSEP, and the Danish MS Registry. The analysis compared MS patients treated with ocrelizumab against cohorts on fingolimod (2,600 vs. 4,103), natalizumab (3,197 vs. 2,437), and alemtuzumab (2,960 vs. 644), all with at least six months of treatment and follow-up.
Results showed that relapse rates were significantly lower in the ocrelizumab group. Specifically, patients on fingolimod experienced a relapse rate of 0.14, whereas those on ocrelizumab had a rate of just 0.06, translating into more than twice the risk of relapse with fingolimod (HR 2.26, 95% CI 1.98–2.58; p<0.001). Additionally, ocrelizumab reduced the likelihood of relapse-related worsening and was associated with a marginal, though statistically significant, difference in comparison with natalizumab and alemtuzumab.
The study also evaluated treatment tolerability through persistence rates, noting that only 8% of natalizumab and 6% of ocrelizumab patients discontinued treatment due to poor tolerability, indicating good tolerability for both therapies.
While ocrelizumab effectively decreased relapses, it did not show significant advantages in slowing disease progression or enhancing disability improvement compared to other therapies. Dr. Izanne Roos, the study's lead author, emphasized that although the reductions in relapse rates are meaningful, they are modest and most pronounced among patients with recent disease activity or prior treatment failure.
The findings underscore the importance of targeting relapse-independent progression in MS, as current therapies managing relapses alone may not fully address long-term disability. Continued research is needed to develop treatments that can more effectively modify disease progression beyond relapse control.
Source: medicalxpress.com
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Nonlinear Neural Network Model Sheds Light on How Fruit Flies Simplify Odor Information
A groundbreaking nonlinear neural network model developed by RIKEN researchers simulates how fruit fly brains simplify odor information. This biomimetic approach enhances understanding of neural plasticity and sensory processing.
Maple Leafs' Goalkeeper Anthony Stolarz's Injury Sparks Concerns Over Concussions in Ice Hockey
The injury of Maple Leafs' goalie Anthony Stolarz during the playoffs highlights ongoing concerns about concussion risks and brain injuries in ice hockey, emphasizing the need for improved prevention and management strategies.
Advancements and Challenges in Post-Traumatic Epilepsy Research After 30 Years
A comprehensive review highlights 30 years of progress in understanding post-traumatic epilepsy, emphasizing advancements in research, potential therapies, biomarkers, and future challenges in preventing epilepsy after brain injury.
Inappropriate Prescriptions in Urgent Care: A Growing Concern
Urgent care centers are facing challenges with overprescription of antibiotics, glucocorticoids, and opioids, highlighting the need for improved prescribing practices to enhance patient safety.